pubmed.ncbi.nlm.nih.gov

Pharmacological interventions for the treatment of obstructive sleep apnea syndrome - PubMed

  • ️Mon Jan 01 2024

Pharmacological interventions for the treatment of obstructive sleep apnea syndrome

Jin Liu et al. Front Med (Lausanne). 2024.

Abstract

Obstructive Sleep Apnea Syndrome (OSAS) affects 13-33% of males and 6-9% of females globally and poses significant treatment challenges, including poor adherence to Continuous Positive Airway Pressure (CPAP) and residual excessive sleepiness (RES). This review aims to elucidate the emerging interest in pharmacological treatments for OSAS, focusing on recent advancements in this area. A thorough analysis of extensive clinical trials involving various drugs, including selective dopamine reuptake inhibitors, selective norepinephrine inhibitors, combined antimuscarinic agents, and orexin agonists, was conducted. These trials focused on ameliorating respiratory metrics and enhancing sleep quality in individuals affected by OSAS. The studied pharmacological agents showed potential in improving primary outcomes, notably the apnea-hypopnea index (AHI) and the Epworth sleepiness scale (ESS). These improvements suggest enhanced sleep quality and symptom management in OSAS patients. With a deeper understanding of OSAS, pharmacological interventions are emerging as a promising direction for its effective management. This review provides a comprehensive overview of the current state of drug research in OSAS, highlighting the potential of these treatments in addressing the disorder's complex challenges.

Keywords: CPAP; ESS; OSAS; pharmacological treatments; respiratory disorder.

Copyright © 2024 Liu, Yang, Li and Liu.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1

Pharmacological action in OSAS treatment. (A) Depicts the specific action mechanisms of Modafinil, Pitolisant, and Solriamfetol in treating OSAS. (B) Illustrates the broader pharmacological pathways and interactions of these medications.

Similar articles

References

    1. Iannella G, Vicini C, Colizza A, Meccariello G, Polimeni A, Greco A, et al. Aging effect on sleepiness and apneas severity in patients with obstructive sleep apnea syndrome: A meta-analysis study. Eur Arch Otorhinolaryngol. (2019) 276:3549–56. 10.1007/s00405-019-05616-0 - DOI - PubMed
    1. Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, et al. Prevalence of obstructive sleep apnea in the general population: A systematic review. Sleep Med Rev. (2017) 34:70–81. 10.1016/j.smrv.2016.07.002 - DOI - PubMed
    1. Mukherjee S, Saxena R, Palmer LJ. The genetics of obstructive sleep apnoea. Respirology. (2018) 23:18–27. 10.1111/resp.13212 - DOI - PMC - PubMed
    1. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet. (2014) 383:736–47. 10.1016/s0140-6736(13)60734-5 - DOI - PMC - PubMed
    1. Lévy P, Kohler M, McNicholas WT, Barbé F, McEvoy RD, Somers VK, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Prim. (2015) 1:15015. 10.1038/nrdp.2015.15 - DOI - PubMed

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from the Natural Science Foundation of Hubei Province, China (No. 2023AFD074).

LinkOut - more resources